HT-001 Phase 2a Interim Data Shows Strong Efficacy; Hoth Therapeutics Secures EU Trial Authorization
Summary
Hoth Therapeutics announced highly positive interim Phase 2a data for its HT-001 drug candidate, indicating the primary efficacy endpoint was achieved by week 6, with over 65% of patients reporting meaningful reductions in pain and itching. Crucially, no treatment-limiting adverse events were observed, and no patients required dose reduction or discontinuation of EGFR inhibitor therapy. Concurrently, the company secured European authorization in Spain for the HT-001 Phase 2a trial. This significant clinical progress provides a much-needed positive catalyst for the micro-cap biotech, especially following its recent Nasdaq non-compliance notification regarding the minimum bid price and ongoing auditor concerns about its ability to continue as a going concern. Strong clinical data is vital for Hoth Therapeutics to attract future funding and partnerships, potentially mitigating its severe financial challenges. Traders will be closely monitoring further clinical updates and any related financing developments.
At the time of this announcement, HOTH was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6M. The 52-week trading range was $0.49 to $2.12. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.